# US 2019/0314426 A1 · Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314426 A1
- Document ID: US20190314426A1
- Status: Published application
- Kind: A1
- Application number: 16/427,899
- Filed: 2019-05-31
- Published: 2019-10-17
- Earliest claimed: 2011-12-01
- Assignees: The University of Tokyo; School Corporation, Azabu Veterinary Medicine Educational Institution
- Applicants: The University of Tokyo; School Corporation, Azabu Veterinary Medicine Educational Institution
- Inventors: Kenya Honda; Koji Atarashi; Takeshi Tanoue; Masahira Hattori; Hidetoshi Morita
- Web page: https://patentgrep.com/patent/US20190314426A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/745: Bifidobacteria
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 33/00: Antiparasitic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- C12Q 1/689: for bacteria
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- C12Q 2600/156: Polymorphic or mutational markers
- C12R 2001/145: Clostridium
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

## Claims

### Claim 1

A method of treating autoimmune disease in a subject, the method comprising administering a pharmaceutical composition comprising a purified bacterial mixture consisting of bacteria comprising 16S rDNA sequences of at least 95% homology to SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:39; SEQ ID NO:40, SEQ ID NO:41, and SEQ ID NO:42 to the subject in an amount sufficient to treat autoimmune disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the autoimmune disease is organ transplant rejection, inflammatory bowel disease (IBD), ulcerative colitis, pouchitis, Crohn's disease, sprue, rheumatoid arthritis, Type 1 diabetes, graft versus host disease, or multiple sclerosis.

### Claim 3 (depends on 2)

The method of claim 2, wherein the autoimmune disease is inflammatory bowel disease (IBD), ulcerative colitis, pouchitis, or Crohn's disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the bacteria are human-derived bacteria.

### Claim 5 (depends on 1)

The method of claim 1, wherein the bacteria are isolated from a chloroform-treated fecal sample.

### Claim 6 (depends on 1)

The method of claim 1, wherein the bacteria are isolated from a heat-treated fecal sample.

### Claim 7 (depends on 1)

The method of claim 1, wherein at least a portion of the bacteria are in spore-form.

### Claim 8 (depends on 1)

The method of claim 1, further comprising a pharmaceutically acceptable excipient.

### Claim 9 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is formulated for oral administration.

### Claim 10 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises one or more enteric polymers.
